3.2 Cardiovascular & Renal Pharmacology
Key Takeaways
- ACE inhibitors (e.g., ramipril, lisinopril) lower blood pressure by blocking Angiotensin II production and preventing bradykinin degradation, which frequently causes a persistent dry cough and rare angioedema.
- Diuretics exert site-specific nephron actions: loop diuretics (furosemide) block the Na+/K+/2Cl- co-transporter in the thick ascending limb causing profound natriuresis and calcium excretion, whereas thiazides block Na+/Cl- in the distal tubule and enhance calcium reabsorption.
- Direct oral anticoagulants (DOACs) directly inhibit specific coagulation factors: apixaban, rivaroxaban, and edoxaban target Factor Xa, whereas dabigatran etexilate directly inhibits Factor IIa (thrombin).
- Warfarin competitively inhibits vitamin K epoxide reductase (VKORC1), depleting functional factors II, VII, IX, and X; its anticoagulant effect requires regular INR monitoring (target range 2.0–3.0) and is reversed by phytomenadione (Vitamin K1) or prothrombin complex concentrate (PCC).
- Statins competitively inhibit HMG-CoA reductase to upregulate hepatic LDL receptors and lower circulating LDL-cholesterol; co-administration with strong CYP3A4 inhibitors increases the risk of statin-induced myopathy and rhabdomyolysis.
Last updated: July 2026
3.2 Cardiovascular & Renal Pharmacology
Quick Reference: Cardiovascular and renal therapeutics represent a major pillar of clinical pharmacy practice. Mastery of mechanisms of action, hemodynamic actions, adverse effect profiles, drug interactions, and electrolyte disturbances is essential for managing hypertension, heart failure, thromboembolism, and ischemic heart disease.
Cardiovascular and renal systems are tightly integrated through pressure-natriuresis, the Renin-Angiotensin-Aldosterone System (RAAS), and autonomic reflexes. Pharmacological interventions modulate fluid balance, vascular tone, cardiac contractility, and haemostasis.
Antihypertensive Classes & Haemodynamic Mechanisms
Hypertension management relies on five primary drug classes, chosen based on patient age, ethnicity, and comorbidities (e.g., diabetes, chronic kidney disease).
1. ACE Inhibitors (ACEi) & Angiotensin Receptor Blockers (ARBs)
- ACE Inhibitors (Ramipril, Lisinopril, Enalapril, Perindopril):
- Mechanism: Inhibit Angiotensin Converting Enzyme (kininase II), blocking conversion of Angiotensin I to Angiotensin II. Reduces vasoconstriction, aldosterone release, and renal sodium reabsorption.
- Kinins & Adverse Effects: ACE also degrades bradykinin and substance P. ACE inhibition causes bradykinin accumulation in lungs, leading to a persistent dry cough (10–20% of patients) and life-threatening angioedema.
- Contraindications: Pregnancy (teratogenic; renal dysgenesis), bilateral renal artery stenosis (causes acute renal failure due to loss of efferent arteriolar tone), hyperkalaemia.
- Angiotensin II Receptor Blockers (Losartan, Valsartan, Candesartan, Telmisartan):
- Mechanism: Competitive antagonists at the $\text{AT}_1$ receptor, selectively blocking Angiotensin II effects without affecting bradykinin metabolism.
- Clinical Role: Direct alternative for patients who develop ACEi-induced cough or mild angioedema.
2. Calcium Channel Blockers (CCBs)
- Dihydropyridines (Amlodipine, Felodipine, Nifedipine):
- Mechanism: Block L-type voltage-gated calcium channels in vascular smooth muscle, causing arterial vasodilation and SVR reduction.
- Adverse Effects: Peripheral ankle edema (due to preferential arteriolar dilation), flushing, reflex tachycardia.
- Non-Dihydropyridines (Verapamil, Diltiazem):
- Mechanism: Block L-type calcium channels in cardiac SA/AV nodes and myocardium. Verapamil is cardioselective (negative inotrope and chronotrope); diltiazem has intermediate cardiac and vascular effects.
- Caution: Contraindicated in heart failure with reduced ejection fraction (HFrEF) and severe bradycardia. Never combine verapamil with $\beta$-blockers due to risks of fatal AV block and severe heart failure.
3. Beta-Adrenoceptor Blockers ($\beta$-Blockers)
- Cardioselective ($\beta_1$): Bisoprolol, Atenolol, Metoprolol. Reduce HR, cardiac output, and juxtaglomerular renin release.
- Non-Selective ($\beta_1 + \beta_2$): Propranolol, Sotalol. Propranolol crosses BBB (used for migraine prophylaxis, essential tremor, performance anxiety).
- Alpha-1 / Beta Blockers: Carvedilol, Labetalol. Cause peripheral vasodilation alongside cardiac blockade; labetalol is preferred in gestational hypertension and hypertensive emergencies.
- Adverse Effects & Cautions: Bronchospasm in asthmatics (avoid non-selective $\beta$-blockers), fatigue, cold extremities, masking of hypoglycaemic warning signs (sweating is preserved).
Diuretic Therapeutics & Nephron Site Action
Diuretics promote natriuresis and diuresis by inhibiting specific solute transporters along distinct nephron segments.
| Class | Representative Drugs | Primary Site of Action | Molecular Target | Electrolyte Profile | Key Clinical Indications & Adverse Effects |
|---|---|---|---|---|---|
| Carbonic Anhydrase Inhibitors | Acetazolamide | Proximal Convoluted Tubule (PCT) | Membrane & cytoplasmic Carbonic Anhydrase | $\uparrow \text{HCO}_3^-$, $\uparrow \text{Na}^+$, $\uparrow \text{K}^+$ | Glaucoma, acute mountain sickness, metabolic alkalosis. Adverse: Hyperchloremic metabolic acidosis |
| Loop Diuretics | Furosemide, Bumetanide, Torsemide | Thick Ascending Limb (TAL) of Henle | $\text{Na}^+/\text{K}^+/2\text{Cl}^-$ co-transporter (NKCC2) | $\downarrow \text{Na}^+$, $\downarrow \text{K}^+$, $\downarrow \text{Mg}^{2+}$, $\downarrow \text{Ca}^{2+}$ | Acute pulmonary edema, heart failure fluid overload, renal failure. High ceiling diuretic. Adverse: Ototoxicity, hypokalemic metabolic alkalosis, hyperuricemia |
| Thiazides & Thiazide-like | Hydrochlorothiazide, Bendroflumethiazide, Indapamide, Chlortalidone | Distal Convoluted Tubule (DCT) | $\text{Na}^+/\text{Cl}^-$ co-transporter (NCCT) | $\downarrow \text{Na}^+$, $\downarrow \text{K}^+$, $\downarrow \text{Mg}^{2+}$, $\uparrow \text{Ca}^{2+}$ | Essential hypertension, calcium nephrolithiasis. Adverse: Hypokalemic metabolic alkalosis, hyperuricemia (gout), hyperglycemia, hyperlipidemia |
| Potassium-Sparing (ENaC Blockers) | Amiloride, Triamterene | Cortical Collecting Duct (CCD) | Epithelial Sodium Channel (ENaC) | $\downarrow \text{Na}^+$, $\uparrow \text{K}^+$, $\downarrow \text{H}^+$ | Combined with loop/thiazides to prevent hypokalemia. Adverse: Hyperkalemia, metabolic acidosis |
| Aldosterone Antagonists (MRAs) | Spironolactone, Eplerenone | Cortical Collecting Duct (CCD) | Nuclear Mineralocorticoid Receptor (MR) | $\downarrow \text{Na}^+$, $\uparrow \text{K}^+$, $\downarrow \text{H}^+$ | Heart failure (reduces mortality), post-MI, primary aldosteronism (Conn's syndrome). Adverse: Hyperkalemia, gynecomastia/anti-androgenic effects (spironolactone > eplerenone) |
Anticoagulant Pharmacotherapy
Anticoagulants prevent thrombus formation and propagation by interfering with the coagulation cascade.
Parenteral Anticoagulants
- Unfractionated Heparin (UFH): Binds antithrombin III (AT-III), accelerating inhibition of Thrombin (Factor IIa) and Factor Xa (1:1 ratio). Monitored via aPTT (target 1.5–2.5x control). Reversed rapidly by Protamine Sulfate.
- Low Molecular Weight Heparins (LMWH: Enoxaparin, Dalteparin): Smaller fragments with higher anti-Xa to anti-IIa activity ratio (~3:1). Predictable pharmacokinetics; renal excretion; minimal monitoring required (Anti-Xa assay used in renal failure/obesity). Risk of Heparin-Induced Thrombocytopenia (HIT) is lower than UFH.
- Fondaparinux: Synthetic pentasaccharide; selective Factor Xa inhibitor via AT-III.
Oral Anticoagulants
-
Vitamin K Antagonist (Warfarin):
- Mechanism: Inhibits Vitamin K Epoxide Reductase Complex 1 (VKORC1), preventing gamma-carboxylation of Factors II, VII, IX, X and endogenous proteins C and S.
- Monitoring: INR (International Normalised Ratio). Target INR is 2.0–3.0 for AF/DVT/PE; 2.5–3.5 for mechanical prosthetic heart valves.
- Reversal: Urgent reversal = Prothrombin Complex Concentrate (PCC / Beriplex) + IV Phytomenadione (Vitamin K1).
- Interactions: Substrate of CYP2C9; sensitive to dietary vitamin K, antibiotics, azoles, and enzyme inducers.
-
Direct Oral Anticoagulants (DOACs):
- Direct Factor Xa Inhibitors: Apixaban, Rivaroxaban, Edoxaban. Rapid onset, fixed dosing, no routine monitoring needed. Specific reversal agent: Andexanet Alfa.
- Direct Thrombin (IIa) Inhibitor: Dabigatran Etexilate. Prodrug excreted 80% renally. Specific reversal agent: Idarucizumab (Praxbind).
Antiplatelet Agents & Lipid-Lowering Therapies
Antiplatelet Regimens
- Cyclooxygenase Inhibitor (Aspirin): Irreversibly acetylates COX-1, blocking Thromboxane $A_2$ ($TXA_2$) synthesis for the 7–10 day lifespan of the platelet.
- $\text{P2Y}_{12}$ ADP Receptor Antagonists:
- Clopidogrel: Irreversible prodrug bioactivated by CYP2C19. Co-administration with CYP2C19 inhibitors (e.g., omeprazole) reduces active metabolite formation and increases thrombotic risk.
- Prasugrel & Ticagrelor: More potent $\text{P2Y}_{12}$ inhibitors. Ticagrelor is reversible and does not require hepatic bioactivation.
Lipid-Lowering Therapeutics
- HMG-CoA Reductase Inhibitors (Statins: Atorvastatin, Rosuvastatin, Simvastatin):
- Mechanism: Competitive inhibition of HMG-CoA reductase (rate-limiting step in mevalonate/cholesterol synthesis), upregulating hepatic LDL receptors to clear circulating LDL-C.
- Adverse Effects: Myalgia, elevated creatine kinase (CK), rhabdomyolysis, elevated liver transaminases. Risk multiplied when combined with CYP3A4 inhibitors (e.g., macrolides, azoles, verapamil) or fibrates.
- Ezetimibe: Inhibits NPC1L1 transporter at enterocyte brush border, blocking dietary and biliary cholesterol absorption.
- PCSK9 Inhibitors (Evolocumab, Alirocumab): Subcutaneous monoclonal antibodies preventing PCSK9-mediated LDL receptor degradation, lowering LDL-C by 50–60%.
- Fibrates (Fenofibrate, Gemfibrozil): PPAR-$\alpha$ agonists that increase LPL activity; primary treatment for severe hypertriglyceridemia (>5.0 mmol/L) to prevent acute pancreatitis.
Test Your Knowledge
Which characteristic metabolic or electrolyte disturbance distinguishes loop diuretics (such as furosemide) from thiazide diuretics (such as hydrochlorothiazide)?
A
B
C
D
Test Your Knowledge
A patient receiving dabigatran etexilate for non-valvular atrial fibrillation presents with emergency life-threatening gastrointestinal bleeding. Which specific monoclonal antibody fragment acts as an immediate reversal agent for dabigatran?
A
B
C
D
Test Your Knowledge
Clopidogrel is a prodrug requiring bioactivation by hepatic cytochrome P450 enzymes. Concurrent administration of which proton pump inhibitor (PPI) significantly reduces clopidogrel efficacy by inhibiting CYP2C19?
A
B
C
D
Test Your Knowledge
What is the primary biochemical mechanism responsible for the persistent dry cough experienced by patients initiated on ACE inhibitor therapy (e.g., ramipril)?
A
B
C
D